Russia Venture Fund, AstraZeneca Sign MOU To Develop Targeted Drugs
This article was originally published in PharmAsia News
A Russian venture fund has signed a memorandum of understanding with AstraZeneca PLC to cooperate in creating an infrastructure for developing personalized drugs.
You may also be interested in...
The EU pharmaceutical strategy published on 25 November will be the first step in a “complete overhaul” of the medicines legislative framework to be proposed in about two years’ time, says the European Commission.
The European Commission’s newly-published Pharmaceutical Strategy features a range of proposals related to generics and biosimilars, including “targeted policies” to improve competition, remove barriers and increase uptake.
Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.